Envestnet Portfolio Solutions Inc. boosted its holdings in United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 8.1% during the fourth quarter, according to its most recent Form 13F filing with the ...

United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company had revenue of $735.90 million for the quarter, compared to the consensus estimate of $734.74 million.

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., March 04, 2025--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that James ...

BofA lowered the firm’s price target on United Therapeutics (UTHR) to $314 from $328 and keeps an Underperform rating on the shares. The firm thinks the challenges to owning United in 2025 are ...

FSU football's quarterback Brock Glenn speaks on the first 3 spring practices, competing with teammate Thomas Castellanos and playing Gus Malzahn's offense Peter Holland Jr. WATCH: Darius ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., March 04, 2025--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Molecular Partners (MOLN – Research Report), United Therapeutics (UTHR – Research Report ...

Investors in United Therapeutics Corp (Symbol: UTHR) saw new options become available this week, for the November 21st expiration. One of the key inputs that goes into the price an option buyer is ...

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide an overview and update on the ...

We recently published a list of 10 Best Healthcare Stocks For Long-Term Investment. In this article, we are going to take a look at where United Therapeutics Corporation (NASDAQ:UTHR) stands against ...